# Schroders Capital raises over $600 million for Global Innovation XI fund targeting AI and healthcare breakthroughs



Schroders Capital, the private markets division of the multinational asset management company Schroders, has successfully concluded its Schroders Capital Private Equity Global Innovation XI Fund, raising over $600 million from a diverse cohort of global investors. These include prominent pension funds, insurance companies, foundations, and family offices, reflecting a robust interest in private equity investments that promise innovation and growth.

The fund’s investment strategy spans the entirety of the investment lifecycle, encompassing primary commitments in new venture funds, co-investments, and secondary purchases. This holistic approach enables investors to gain exposure to a diversified portfolio of companies across various stages, sectors, and regions, with a strong emphasis on technology innovation. Notably, the fund aims to harness the transformative capabilities of generative AI, demonstrated by its investment in Scale AI, a leader in AI data services essential for accelerating the development of AI applications.

This recent fundraising is part of a broader narrative of Schroders Capital’s evolution in the private equity space, where, since 1997, its Global Innovation team has deployed over $6.5 billion into venture and growth investments globally. The emergence of demand for innovative investment structures was highlighted last year with the launch of the UK’s first venture and growth Long-Term Asset Fund (LTAF), which recently closed with £500 million in commitments. This fund has already made pivotal investments in UK-based AI firms such as Synthesia and Luminance.

Steven Yang, the Head of Global Innovation at Schroders Capital, expressed confidence in the fund's success, stating, “The strong fundraising momentum and successful closing of Global Innovation XI underscores our commitment to delivering exceptional value and innovative solutions for our investors.” He further remarked on the rapid pace of disruptive innovation globally, noting that sectors like technology, artificial intelligence, and biopharma are at the forefront of investment opportunities.

Additionally, the trust associated with Schroders Capital, the Global Innovation Trust, continues to thrive. As of the end of December 2023, its portfolio comprises a significant collection of quoted and unquoted companies primarily within the technology and healthcare sectors. Notable holdings include Oxford Nanopore Technologies and Atom Bank. The trust is structured to support businesses with promising growth trajectories, mirroring the strategic objectives of the broader private equity investments managed by Schroders.

Highlighting the success of its investment strategy, the Global Innovation Trust recently experienced a surge in its share value following the announcement of a notable acquisition involving its investee, Araris Biotech AG, by Taiho Pharmaceutical Co Ltd for $400 million upfront, with potential additional payments. Such developments not only validate the fund's strategic approach but also bolster investor confidence in Schroders Capital’s capacity to deliver substantial returns.

In the sphere of healthcare innovation, the Global Innovation Trust also invested $1.6 million in Neurona Therapeutics, a clinical-stage cell therapy company. This investment aligns with an ongoing commitment to address unmet healthcare needs, particularly in chronic neurological disorders, underscoring Schroders’ proactive approach to fostering transformative healthcare solutions within its investment portfolio.

As the landscape of venture capital continues to evolve, Schroders Capital appears well-positioned to capture emerging growth opportunities, bolstered by its established relationships and diversified investment strategies.

### 📌 Reference Map:

* Paragraph 1 – [[1]](https://pulse2.com/schroders-capital-over-600-million-raised-for-private-equity-global-innovation-xi-fund/), [[4]](https://www.schroderscapital.com/en/global/professional/capabilities/private-equity/)
* Paragraph 2 – [[1]](https://pulse2.com/schroders-capital-over-600-million-raised-for-private-equity-global-innovation-xi-fund/), [[2]](https://www.schroders.com/en-gb/uk/individual/funds-and-strategies/investment-trusts/schroders-capital-global-innovation-trust/), [[5]](https://www.morningstar.co.uk/uk/news/AN_1742220831319866600/schroders-capital-global-leaps-as-investee-sold-for-usd400-million.aspx)
* Paragraph 3 – [[3]](https://www.schroders.com/en-gb/uk/intermediary/funds-and-strategies/investment-trusts/schroders-capital-global-innovation-trust/portfolio/), [[6]](https://www.morningstar.co.uk/uk/news/AN_1707472236707128400/schroders-capital-global-innovation-injects-usd16-million-in-neurona.aspx)
* Paragraph 4 – [[1]](https://pulse2.com/schroders-capital-over-600-million-raised-for-private-equity-global-innovation-xi-fund/), [[7]](https://www.privateequitywire.co.uk/schroders-capital-raises-2-6bn-in-pe-direct-and-co-investments/)

Source: [Noah Wire Services](https://www.noahwire.com)

## Bibliography

1. <https://pulse2.com/schroders-capital-over-600-million-raised-for-private-equity-global-innovation-xi-fund/> - Please view link - unable to able to access data
2. <https://www.schroders.com/en-gb/uk/individual/funds-and-strategies/investment-trusts/schroders-capital-global-innovation-trust/> - Schroders Capital Global Innovation Trust is a UK-listed investment trust focusing on long-term investments in innovative companies across various sectors. Managed by Schroders Capital, the trust aims to provide investors with exposure to global innovation opportunities, leveraging Schroders' extensive experience in private equity and venture capital. The trust's portfolio includes a diverse range of companies, with a significant emphasis on technology and healthcare sectors, reflecting the managers' strategy to invest in businesses with high growth potential and transformative capabilities.
3. <https://www.schroders.com/en-gb/uk/intermediary/funds-and-strategies/investment-trusts/schroders-capital-global-innovation-trust/portfolio/> - As of 31 December 2023, the Schroders Capital Global Innovation Trust's portfolio comprises a mix of quoted and unquoted companies, with a notable focus on technology and healthcare sectors. Key holdings include Oxford Nanopore Technologies, Atom Bank, and Revolut. The trust's investment strategy aims to identify and support innovative businesses with strong growth prospects, aligning with Schroders Capital's broader approach to private equity investments that seek to transform and scale companies across the globe.
4. <https://www.schroderscapital.com/en/global/professional/capabilities/private-equity/> - Schroders Capital's Private Equity division manages over $21 billion in assets, focusing on responsible growth and business transformation across the entire company lifecycle, from seed capital to buyouts. The team leverages decades of expertise to identify attractive investment opportunities, with a strong commitment to Environmental, Social, and Governance (ESG) principles integrated into each investment decision. Their global reach and local networks enable them to capture opportunities in emerging businesses with high potential for sustainable growth and value creation.
5. <https://www.morningstar.co.uk/uk/news/AN_1742220831319866600/schroders-capital-global-leaps-as-investee-sold-for-usd400-million.aspx> - Schroders Capital Global Innovation Trust's shares surged following the announcement that its investee, Araris Biotech AG, is set to be acquired by Taiho Pharmaceutical Co Ltd for $400 million upfront, with potential additional milestone payments of up to $740 million. This deal significantly increased the valuation of Schroders Capital's holding in Araris, highlighting the trust's successful investment strategy in the biotechnology sector and its ability to generate substantial returns for investors.
6. <https://www.morningstar.co.uk/uk/news/AN_1707472236707128400/schroders-capital-global-innovation-injects-usd16-million-in-neurona.aspx> - Schroders Capital Global Innovation Trust invested $1.6 million in Neurona Therapeutics, a California-based clinical-stage cell therapy company, as part of its Series E funding round. This investment aligns with the trust's strategy to support innovative life science companies at near-clinical or clinical stages, aiming to address unmet needs in chronic neurological disorders. The funding is intended to advance Neurona's pipeline of off-the-shelf cell therapies, reflecting the trust's commitment to transformative healthcare solutions.
7. <https://www.privateequitywire.co.uk/schroders-capital-raises-2-6bn-in-pe-direct-and-co-investments/> - Schroders Capital, the private markets arm of Schroders Group, has successfully raised over $2.6 billion for private equity direct and co-investments since January 2022. This includes the €400 million close of Schroders Capital Private Equity Europe Direct III, which attracted strong support from a diverse group of global investors. The fund focuses on delivering business transformations with low financial leverage, targeting high-growth potential European SMEs, and has achieved significant returns on invested capital through recent exits.